Skip to content

Deciphering Disease Mechanisms Through Functional Genomics

Deciphering Disease Mechanisms Through Functional Genomics

Deciphering Disease Mechanisms Through Functional Genomics

Deciphering Disease Mechanisms Through Functional Genomics

Are you interested in learning about disease mechanisms through functional genomics? Join us for a webinar with Prof. Dr. Vijay Tiwari from the Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, UK & Institute of Molecular Medicine, SDU, Denmark. The webinar will take place in less than a week, on Wed, Apr 19, 2023, at 3:00 PM CET.

The research in Tiwari lab aims at achieving an integrated molecular and systems-level understanding of the communication between genetic and epigenetic information in determining cell identity and how this communication is altered in cancer and neurological disorders. To investigate these questions, Tiwari lab employs a multidisciplinary approach combining cutting-edge genomics and epigenetics together with computational biology tools in defined animal and cellular models. Most recently, using single-cell transcriptome profiles of TNBC patients, Tiwari lab has identified subclonal cell populations associated with chemoresistance. They further revealed the underlying gene regulatory circuitry and developed a first-in-class multi-gene assay for predicting chemotherapy response upfront for TNBC patients with high accuracy. Furthermore, they show that targeting these signature genes offers avenues to overcome resistance. These findings shed light on the mechanistic basis of chemoresistance while providing the best-in-class biomarker to predict chemotherapy response and alternate therapeutic routes for improved management of TNBC patients resistant to chemotherapy.

The format is the following:

  • 5 mins – introduction
  • 30 mins – main discussion
  • 10 min+ – Q&A

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News

01 /04

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

02 /04

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

04 /04

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News